Pershing Edward 13D and 13G filings for Provectus Biopharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-07-22 3:04 pm Purchase | 2026-06-30 | 13D | PROVECTUS BIOPHARMACEUTICALS, PVCT | Pershing Edward | 52,441,275 11.610% | 3,185,381 (+6.47%) | Filing |
| 2025-12-01 9:52 pm Purchase | 2025-11-26 | 13D | PROVECTUS BIOPHARMACEUTICALS, PVCT | Pershing Edward | 49,255,894 10.560% | 12,842,797 (+35.27%) | Filing |
| 2024-12-06 7:45 pm Purchase | 2024-12-02 | 13D | PROVECTUS BIOPHARMACEUTICALS, PVCT | Pershing Edward | 36,413,097 8.030% | 13,778,047 (+60.87%) | Filing |
| 2024-07-03 7:29 pm Purchase | 2024-06-26 | 13D | PROVECTUS BIOPHARMACEUTICALS, PVCT | Pershing Edward | 22,635,050 5.170% | 22,635,050 (New Position) | Filing |